Oncolys BioPharma Inc. (4588.T)
JPY 556.0
(-2.11%)
JPY 556.0
(-2.11%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 161.1 Million JPY | -0.74% |
| 2022 | 162.3 Million JPY | -38.03% |
| 2021 | 261.91 Million JPY | -29.77% |
| 2020 | 372.92 Million JPY | -6.14% |
| 2019 | 397.29 Million JPY | 27.16% |
| 2018 | 312.44 Million JPY | -11.13% |
| 2017 | 351.58 Million JPY | 11.51% |
| 2016 | 315.29 Million JPY | -2.97% |
| 2015 | 324.96 Million JPY | -11.15% |
| 2014 | 365.75 Million JPY | 2.02% |
| 2013 | 358.52 Million JPY | 57.1% |
| 2012 | 228.21 Million JPY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 194.43 Million JPY | 40.0% |
| 2024 Q1 | 138.88 Million JPY | -13.79% |
| 2023 Q2 | 199.37 Million JPY | 37.76% |
| 2023 Q1 | 144.72 Million JPY | -10.83% |
| 2023 Q4 | 161.1 Million JPY | -8.59% |
| 2023 Q3 | 176.23 Million JPY | -11.61% |
| 2023 FY | 161.1 Million JPY | -0.74% |
| 2022 Q4 | 162.3 Million JPY | -9.77% |
| 2022 FY | 162.3 Million JPY | -38.03% |
| 2022 Q1 | 239.02 Million JPY | -8.74% |
| 2022 Q2 | 291.88 Million JPY | 22.12% |
| 2022 Q3 | 179.87 Million JPY | -38.37% |
| 2021 Q2 | 391.04 Million JPY | -3.62% |
| 2021 Q3 | 373.7 Million JPY | -4.43% |
| 2021 Q4 | 261.91 Million JPY | -29.91% |
| 2021 FY | 261.91 Million JPY | -29.77% |
| 2021 Q1 | 405.74 Million JPY | 8.8% |
| 2020 Q1 | 441.09 Million JPY | 11.02% |
| 2020 FY | 372.92 Million JPY | -6.14% |
| 2020 Q2 | 415.59 Million JPY | -5.78% |
| 2020 Q3 | 390.09 Million JPY | -6.14% |
| 2020 Q4 | 372.92 Million JPY | -4.4% |
| 2019 Q1 | 436.96 Million JPY | 39.85% |
| 2019 Q4 | 397.29 Million JPY | -0.76% |
| 2019 Q3 | 400.36 Million JPY | -5.31% |
| 2019 FY | 397.29 Million JPY | 27.16% |
| 2019 Q2 | 422.8 Million JPY | -3.24% |
| 2018 Q3 | 321.49 Million JPY | -2.89% |
| 2018 Q4 | 312.44 Million JPY | -2.81% |
| 2018 FY | 312.44 Million JPY | -11.13% |
| 2018 Q2 | 331.06 Million JPY | -3.0% |
| 2018 Q1 | 341.3 Million JPY | -2.92% |
| 2017 Q2 | 369.88 Million JPY | 17.7% |
| 2017 FY | 351.58 Million JPY | 11.51% |
| 2017 Q4 | 351.58 Million JPY | -2.84% |
| 2017 Q3 | 361.86 Million JPY | -2.17% |
| 2017 Q1 | 314.27 Million JPY | -0.33% |
| 2016 Q4 | 315.29 Million JPY | -0.78% |
| 2016 Q3 | 317.77 Million JPY | -0.77% |
| 2016 Q2 | 320.24 Million JPY | 0.28% |
| 2016 Q1 | 319.34 Million JPY | -1.73% |
| 2016 FY | 315.29 Million JPY | -2.97% |
| 2015 Q4 | 324.96 Million JPY | -2.46% |
| 2015 Q2 | 344.1 Million JPY | -2.3% |
| 2015 FY | 324.96 Million JPY | -11.15% |
| 2015 Q3 | 333.14 Million JPY | -3.18% |
| 2015 Q1 | 352.19 Million JPY | -3.71% |
| 2014 FY | 365.75 Million JPY | 2.02% |
| 2014 Q2 | 364.24 Million JPY | -2.57% |
| 2014 Q1 | 373.87 Million JPY | 4.28% |
| 2014 Q4 | 365.75 Million JPY | -1.01% |
| 2014 Q3 | 369.48 Million JPY | 1.44% |
| 2013 FY | 358.52 Million JPY | 57.1% |
| 2013 Q4 | 358.52 Million JPY | 0.0% |
| 2012 FY | 228.21 Million JPY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 767.03 Million JPY | 78.997% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 2 Billion JPY | 91.945% |
| Linical Co., Ltd. | 1.49 Billion JPY | 89.26% |
| Trans Genic Inc. | 1.32 Billion JPY | 87.861% |
| MEDINET Co., Ltd. | 781 Thousand JPY | -20527.401% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.34 Billion JPY | 93.136% |
| AnGes, Inc. | 214.94 Million JPY | 25.052% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | -50.774% |
| Nxera Pharma Co., Ltd. | 63.21 Billion JPY | 99.745% |
| Immuno-Biological Laboratories Co., Ltd. | 84.56 Million JPY | -90.513% |
| NanoCarrier Co., Ltd. | 1.1 Billion JPY | 85.472% |
| Carna Biosciences, Inc. | 28.4 Million JPY | -467.214% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 875.59 Million JPY | 81.601% |
| RaQualia Pharma Inc. | 39.05 Million JPY | -312.548% |
| Chiome Bioscience Inc. | - JPY | -Infinity% |
| Kidswell Bio Corporation | 1.83 Billion JPY | 91.235% |
| PeptiDream Inc. | 19.63 Billion JPY | 99.18% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | 397 Million JPY | 59.421% |
| Healios K.K. | 450 Million JPY | 64.2% |
| BrightPath Biotherapeutics Co., Ltd. | - JPY | -Infinity% |
| Kubota Pharmaceutical Holdings Co., Ltd. | - JPY | -Infinity% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 77.29 Million JPY | -108.433% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 773.29 Million JPY | 79.167% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| Takara Bio Inc. | 788 Million JPY | 79.556% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 491.35 Million JPY | 67.213% |
| StemCell Institute Inc. | 6.67 Million JPY | -2313.122% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 143.75 Million JPY | -12.07% |